natgillin/translations-raw huggingface dataset:
1 vial with white powder for solution for injection
1 bočicu s bijelim praškom za otopinu za injekciju
1 vial – 100 mg
1 bočica – 100 mg
1 vial: 1000 IU nonacog alfa (approx.
1 bočica: 1000 IU nonakoga alfa (pribl.
1 vial: 1000 IU octocog alfa (400 IU/ml after reconstitution).
1 bočica: 1000 IU oktokoga alfa (400 IU/ml nakon pripreme za primjenu).
1 vial: 2000 IU nonacog alfa (approx.
1 bočica: 2000 IU nonakoga alfa (pribl.
1 vial: 250 IU nonacog alfa (approx.
1 bočica: 250 IU nonakoga alfa (pribl.
1 vial: 250 IU octocog alfa (100 IU/ml after reconstitution).
1 bočica: 250 IU oktokoga alfa (100 IU/ml nakon pripreme za primjenu).
1 vial: 3000 IU nonacog alfa (approx.
1 bočica: 3000 IU nonakoga alfa (pribl.
1 vial: 500 IU nonacog alfa (approx.
1 bočica: 500 IU nonakoga alfa (pribl.
1 vial: 500 IU octocog alfa (200 IU/ml after reconstitution).
1 bočica: 500 IU oktokoga alfa (200 IU/ml nakon pripreme za primjenu).
1 vial: EU/1/12/798/001
1 bočica: EU/1/12/798/001
1 vial: EU/1/12/798/002
1 bočica: EU/1/12/798/002
1 vial: powder
1 bočica: prašak
1 What AVONEX is and what it is used for
Što je AVONEX i za što se koristi
1 What AVONEX is and what it is used for What AVONEX is
1 Što je AVONEX i za što se koristi Što je AVONEX
1 What TRAVATAN is and what it is used for
Što je TRAVATAN i za što se koristi
1 When data available from drug interaction studies.
1 Kada su podaci dostupni iz ispitivanja interakcija lijekova.
1 While the exact incidence of eosinophilic pneumonia associated with daptomycin is unknown, to date the reporting rate of spontaneous reports is very low (< 1/10,000).
1 Iako je točna incidencija eozinofilne pneumonije povezane s daptomicinom nepoznata, do sada je stopa prijavljivanja spontanih izvješća bila vrlo niska (<1/10 000).
1 With the exception of angioedema and anaemia (see footnotes 2 and 3), all adverse reactions were identified from clinical studies of F/TAF containing products.
1 Osim angioedema i anemije (vidjeti bilješke 2 i 3), sve su nuspojave bile utvrĎene u kliničkim ispitivanjima lijekova koji sadrţe F/TAF.
1 x 0.5 mL injection
1 x 0,5 mL injekcija
1 x 1 mg vial 5x 1 mg vial
1 x1 mg bočica 5x 1 mg bočica
1 x 1 mg vial; 5 x 1 mg vial
1 bočica x 1 mg; 5 bočica x 1 mg
1 x 1,000
1 x 1.000
1 x 1.5 ml single-dose vial 4 x 1.5 ml single-dose vials
1 x 1,5 ml jednodozna bočica 4 x 1,5 ml jednodozne bočice
1 x 10 doses (20 ml)
1 x 10 doza (20 ml)
1 x 10 ml Humalog Mix25 vial.
1 x 10 ml bočica lijeka Humalog Mix25
1 x 10 ml Humalog Mix50 vial.
1 x 10 ml bočica lijeka Humalog Mix50
1 x 10 ml Humalog vial.
1 x 10 ml bočica lijeka Humalog
1 x 10 ml Liprolog vial.
1 x 10 ml bočica lijeka Liprolog
1 X 10 ml vial
1 x 10 ml bočica
1 x 10 ml vial.
Bočica 1 x 10 ml.
1 x 10 ml vials.
Bočice 1 x 10 ml.
1 x 10,000 doses, 10 x 10,000 doses
1 x 10000 doza, 10 x 10000 doza
1 x 100 mg twice daily
1 x 100 mg dvaput na dan
1 x 100 ml
100 ml
1 x 1040 mg tablet
1 tableta od 1040 mg
1 x 10e6 PFU/ml 1 x 10e8 PFU/ml
1x 10e8 PFU/ml
1 x 125 doses (250 ml) 1 x 10 doses (20ml)
1x 125 doza (250 ml)
1 x 14 dose inhaler
1 x 14-dozni inhaler
1 x 140 mg tablet
1 tableta od 140 mg
1 x 1620 mg tablet
1 tableta od 1620 mg
1 x 1620 mg tablet + 1 x 665 mg tablet
1 tableta od 1620 mg + 1 tableta od 665 mg
1 x 180 mg tablet
1 tableta od 180 mg
1 x 180 tablets per bottle
1 x 180 tableta u bočici
1 x 2,000
1 x 2.000
1 x 2,500 doses, 10 x 2,500 doses
1 x 2500 doza, 10 x 2500 doza
1 x 2.5 mL.
1 x 2,5 ml.
1 x 20 film-coated tablets
1 x 20 filmom obloženih tableta
1 x 20 ml
20 ml
1 x 20 ml vial (500 mg/20 ml)
1 x 20 ml bočica (500 mg/20 ml)
1 x 20,000 doses, 10 x 20,000 doses
1 x 20000 doza, 10 x 20000 doza
1 x 25ml bottle.
1 boca x 25 ml.
1 x 270 mg tablet
1 tableta od 270 mg
1 x 3 mL + 7 NovoFine needles 1 x 3 mL + 7 NovoTwist needles 2 x 3 mL
1 x 3 ml + 7 NovoFine igala 1 x 3 ml + 7 NovoTwist igala 2 x 3 ml
1 x 3 ml cartridge
1 x 3 ml uložak
1 x 3 ml cartridge
1 x 3 ml uložak 5 x 3 ml uložaka
1 x 3 ml oral syringe
Štrcaljka za oralnu primjenu, 1 x 3 ml
1 x 3 ml pre-filled pen
1 x 3 ml napunjena brizgalica
1 x 3 ml pre-filled pen + 7 NovoFine needles 1 x 3 ml pre-filled pen + 7 NovoTwist needles
1 x 3 ml napunjena brizgalica + 7 NovoFine igala 1 x 3 ml napunjena brizgalica + 7 NovoTwist igala
1 x 3 ml pre-filled pen 5 x 3 ml pre-filled pens
1 x 3 ml napunjena brizgalica 5 x 3 ml napunjenih brizgalica
1 x 3.5 ml concentrate for solution for infusion 4 x 3.5 ml concentrate for solution for infusion 10 x 3.5 ml concentrate for solution for infusion
1 x 3,5 ml koncentrat za otopinu za infuziju 4 x 3,5 ml koncentrat za otopinu za infuziju 10 x 3,5 ml koncentrat za otopinu za infuziju
1 x 30 capsules
1 x 30 kapsula
1 x 30 dose inhaler
1 x 30–dozni inhaler
1 x 30 tablets per bottle
1 x 30 tableta u bočici
1 x 4 mg vial; 5 x 4 mg vial
1 bočica x 4 mg; 5 bočica x 4 mg
1 x 4 ml vial (100 mg/4 ml)
1 x 4 ml bočica (100 mg/4 ml)
1 x 4,000
1 x 4.000
1 x 40 ml vial (1000 mg/40 ml)
1 x 40 ml bočica (1000 mg/40 ml)
1 x 425 mg tablet
1 tableta od 425 mg
1 x 5 ml vial 4 x 5 ml vials 10 x 5 ml vials
1 x 5 ml bočica 4 x 5 ml bočice 10 x 5 ml bočica
1 x 5,000 doses, 10 x 5,000 doses
1 x 5000 doza, 10 x 5000 doza
1 x 50 ml
1x 50 ml
1 x 50 ml
50 ml
1 x 60 capsules
1 x 60 kapsula
1 x 60 film-coated tablets
1 x 60 filmom obloženih tableta
1 x 60 g granules
1 x 60 g granula
1 x 665 mg tablet
1 tableta od 665 mg
1 x 75 mg vial
1 x 75 mg bočica
1 x 90 mg tablet
1 tableta od 90 mg
1 x single dose (0.5 ml) pre-filled syringe 10 x single dose (0.5 ml) pre-filled syringes
1x jednodozna napunjena štrcaljka (0,5 ml) 10 x jednodozna napunjena štrcaljka (0,5 ml)
1 x1,000
1 x 1.000
1 x10 ml vial.
Bočica 1 x 10 ml.
1 year
1 godina.
1 year CSR Q1 2017
1 godina CSR Q1 2017
1 year old (9.7 kg)
1- godišnjak (9,7 kg)
1 year persistence
Postojanost nakon 1 godine
1 year survival rate
1-godišnja stopa preživljenja
1 year survival,
1-godišnje preživljenje,
1 year to < 5 years
od 1 godine do < 5 godina
1 year –
1 godina
1 years
1 godina
1 yr < 5 yrs
1 god < 5 god
1 Zinbryta 150 mg Pen
1 Zinbryta 150 mg brizgalica
1) and Viramune prolonged-release (randomised-phase/maintenance phase, table 2) groups of clinical study 1100.1486 with 1,068 patients exposed to Viramune on a backbone of tenofovir/emtricitabine.
1) i Viramune s produljenim oslobađanjem (randomizirano razdoblje, razdoblje održavanja, tablica 2) iz kliničkog ispitivanja 1100.1486 s 1068 bolesnika izloženih Viramuneu na osnovnu terapiju tenofovirom/emricitabinom.
1) and Viramune prolonged-release (randomised-phase/maintenance phase, table 2) groups of clinical study 1100.1486 with 1,068 patients exposed to Viramune on a backbone of tenofovir/emtricitabine.
1) i Viramune s produljenim oslobađanjem (razdoblje randomizacije, razdoblje održavanja, tablica 2) iz kliničkog ispitivanja 1100.1486 s 1 068 bolesnika izloženih Viramuneu na osnovnu terapiju tenofovirom/emricitabinom.
1) and Viramune prolonged-release (randomised-phase/maintenance phase, table 2) groups of clinical study 1100.1486 with 1,068 patients exposed to Viramune on a backbone of tenofovir/emtricitabine.
1) i Viramune s produljenim oslobađanjem (razdoblje randomizacije, razdoblje održavanja, tablica 2) iż kliničkog ispitivanja 1100.1486 s 1 068 bolesnika izloženih Viramuneu na osnovnu terapiju tenofovirom/emricitabinom.
1) Frequency was not increased in patients treated with nintedanib plus docetaxel as compared to placebo plus docetaxel.
1) Učestalost se nije povećala u bolesnika liječenih kombinacijom nintedaniba i docetaksela u usporedbi s liječenjem kombinacijom placebo i docetaksel
1), time from diagnosis to randomisation (<1 year vs. ≥1 year), tumour MET status (high vs. low vs. unknown), bone metastases (absence vs. presence), visceral metastases (absence vs. presence), visceral and bone metastases (absence vs. presence), number of prior VEGFR-TKIs (1 vs. ≥2), duration of first VEGFR-TKI (≤6 months vs. >6 months).
1), vremenu od dijagnoze do randomizacije (<1 godine vs. ≥1 godine), MET statusu tumora (visok vs. nizak vs. nepoznat), koštanim metastazama (odsutnost vs. prisutnost), visceralnim metastazama (odsutnost vs. prisutnost), visceralnim i koštanim metastazama (odsutnost vs. prisutnost), broju prethodnih VEGFR-TKI-a (1 vs. ≥2), trajanju primjene prvog VEGFR-TKI (≤6 mjeseci vs. >6 mjeseci).
1+1) vials + ampoules (multi-pack)
+ ampula (višestruko pakiranje)
1, 2 or 3 vials x 0.4 ml
1, 2 ili 3 bočice x 0,4 ml
1, 2, 3, 4: for further descriptions, please see sub-section “Description of selected adverse reactions”
1, 2, 3, 4: za daljnje opise, molimo vidjeti pod “Opis odabranih nuspojava”.
1, 2, 3, 4: for further descriptions, please see sub-section ”Description of selected adverse reactions”.
1, 2, 3, 4: za daljnje opise, molimo vidjeti pod “Opis odabranih nuspojava”.
1, 28700 San Sebastian de los Reyes, Madrid Spain
1, 28700 San Sebastian de los Reyes, Madrid Španjolska
1, 3 and 6 weeks after starting Caprelsa
1, 3 i 6 tjedana nakon početka liječenja lijekom Caprelsa
1, 4, 6 or 10 high density polyethylene (HDPE) bottles containing 10 ml, 20 ml, 50 ml and 100 ml of solvent, closed with a siliconised chlorobutyl rubber stopper with lacquered aluminium seal.
1, 4, 6 ili 10 bočica od polietilena visoke gustoće (HDPE) koje sadrže 10 ml, 20 ml, 50 ml i 100 ml otapala, zatvorenih silikoniziranim čepom od klorobutilne gume i lakiranim aluminjskim nepropusnim zatvaračem.
1, 4, 6 or 10 lyophilisate vials 5 doses, 10 doses, 25 doses or 50 doses and 1, 4, 6 or 10 solvent bottles containing 10 ml, 20 ml, 50 ml or 100 ml respectively in carboard box.
1, 4, 6 ili 10 bočica liofilizata koje sadrže 5 doza, 10 doza, 25 doza ili 50 doza i 1, 4, 6 ili 10 bočica otapala koje sadrže 10 ml, 20 ml, 50 ml odnosno 100 ml u kartonskoj kutiji.
1, 4, 6 or 10 type I amber glass vials containing 5 doses (10 ml), 10 doses (20 ml), 25 doses (50 ml) and 50 doses (100 ml) of lyophilisate, closed with siliconised bromobutyl rubber stopper with lacquered aluminium seal.
1, 4, 6 ili 10 bočica od stakla tipa I, boje jantara koje sadrže 5 doza (10 ml),10 doza (20 ml), 25 doza (50 ml) i 50 doza (100 ml) liofilizata, zatvorenih čepom od silikonizirane bromobutilne gume i lakiranim aluminijskim nepropusnim zatvaračem.
1, 56, 56 x 1, 60, 70, 70 x 1, 98 or 98 x 1 film-coated tablets.
35 x 1, 56, 56 x 1, 60, 70, 70 x 1, 98 ili 98 x 1 filmom obloženih tableta.
1, 79639 Grenzach Wyhlen, Germany.
1, 79639 Grenzach Wyhlen, Njemačka.
1, 79639 Grenzach-Wyhlen, Germany.
1, 79639 Grenzach-Wyhlen, Njemačka.
1, Avenue de la Gare L-1611 Luxembourg Luxembourg
1, Avenue de la Gare L-1611 Luxembourg Luksemburg
1, D-79639 Grenzach-Wyhlen, Germany
1, D-79639 Grenzach-Wyhlen, Njemačka
1, dark peach opaque cap and dark peach opaque body, hard-shell gelatin capsule filled with white to off-white powder.
1 s tamnoružičastom neprozirnom kapicom i tamnoružičastim neprozirnim tijelom napunjena bjeličastim prahom.
1, light peach opaque cap and light peach opaque body, hard-shell gelatin capsule filled with white to off-white powder.
1 sa svjetloružičastom neprozirnom kapicom i svjetloružičastim neprozirnim tijelom napunjena bjeličastim prahom.
1,000 doses
1 000 doza
1,000 doses
1.000 doza
1,000 doses
1000 doza
1,000 IU/0.5 ml
1000 IU/0,5 ml
1,000 mg acetaminophen/paracetamol
1000 mg acetaminofena/paracetamola
1,000 mg dose - Use 1 vial (50 ml total, 50 ml per vial):
Doza od 1000 mg – koristite 1 bočicu (50 ml ukupno, 50 ml po bočici):
1,000 mg dose – Use 1 x 1,000 mg/50 ml vial (50 ml total, 50 ml per vial):
Doza od 1000 mg – koristite 1 bočicu od 1000 mg/50 ml (50 ml ukupno, 50 ml po bočici):
1,000 mg levetiracetam.
750, 1000 mg levetiracetama.
1,000 mg of powder in a glass vial (type I), closed with a rubber (bromobutyl) stopper and an aluminium seal with a plastic flip off cap.
1000 mg praška u staklenoj bočici (staklo tip I) zatvorenoj gumenim (bromobutil) čepom i aluminijskim zatvaračem s plastičnom "flip off" kapicom.
1,000 mg twice daily
1000 mg dva puta na
1,000 mg/day
1000 mg/dan
1,000 patient years, respectively.
0 događaja na 1000 bolesnik godina.
1,000 µg/kg
1.000 µg/kg
1,000,000 cells/cm²
1,000,000 stanica/cm²
1,000/100 mg twice daily
1000/100 mg dva puta
1,000/400/100 mg twice daily
1000/400/100 mg dva puta na dan
1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C4H2F6O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide.
1,1,3,3,3-pentafluoro-2-(fluorometoksi)propen (C4H2F6O), također poznat pod nazivom Spoj A, nastaje interakcijom sevoflurana s mješavinom kalcijevog, natrijevog i kalijevog hidroksida ili barijevog hidroksida.
1,125 mg every 8 hours)
1 125 mg svakih 8 sati)
1,197 patients continued treatment and prevention of recurrent venous thromboembolism
1197 bolesnika koje je nastavilo liječenje i prevenciju ponavljajuće venske tromboembolije
1,2,3,4: for further descriptions, please see sub-section 4“Description of selected adverse reactions”
1, 2, 3, 4: za daljnje opise, molimo vidjeti pod “Opis odabranih nuspojava”.
1,2,3,4: for further descriptions, please see sub-section “Description of selected adverse reactions”
1, 2, 3, 4: za daljnje opise, molimo vidjeti pod “Opis odabranih nuspojava”.
1,2-Dioleoyl-sn-glycero-3-phospho-L-serine monosodium salt (OOPS)
1,2-dioleoil-sn-glicero-3-fosfo-L-serin mononatrijeva sol (OOPS)
1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC)
1,2-dipalmitoil-sn-glicero-3-fosfatidilkolin (DPPC)
1,200 mg)d
do 1200 mg)d
1,200 mg/day
1200 mg/dan
1,200 mg/m2
1200 mg/m2
1,200 μg/kg
1200
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to nevirapine 400 mg once daily, nevirapine 200 mg twice daily, efavirenz 600 mg once daily, or nevirapine (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
1216 bolesnika prethodno neliječenih antiretrovirusnim lijekovima s HIV-1 RNK u plazmi >5000 kopija/ml primali su nevirapin 400 mg jednom dnevno, nevirapin 200 mg dvaput dnevno, efavirenz 600 mg jednom dnevno ili nevirapin (400 mg) i efavirenz (800 mg) jednom dnevno, plus stavudin i lamivudin tijekom 48 tjedana.
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to Viramune 400 mg once daily, Viramune 200 mg twice daily, efavirenz 600 mg once daily, or Viramune (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
1216 bolesnika prethodno neliječenih antiretrovirusnim lijekovima s HIV-1 RNK u plazmi >5000 kopija/ml primali su Viramune 400 mg jednom dnevno, Viramune 200 mg dvaput dnevno, efavirenz 600 mg jednom dnevno ili Viramune (400 mg) i efavirenz (800 mg) jednom dnevno, plus stavudin i lamivudin tijekom 48 tjedana.
1,276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1276 bolesnika (744 u TAX 316 i 532 u GEICAM 9805 studiji) koji su primali docetaksel u kombinaciji s doksorubicinom i ciklofosfamidom (prikazani su klinički značajni štetni događaji povezani s liječenjem),
1,3--D-glucan is not present in mammalian cells.
1,3--D-glukan nije prisutan u stanicama sisavaca.
1,312 and 121 patients who received 100 mg/m2 and 75 mg/ m2 of docetaxel as a single agent respectively.
1312 bolesnika koji su primali 100 mg/m2 i 121 bolesnika koji su primali 75 mg/m2 docetaksela kao monoterapiju,
1,312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1312 bolesnika koji su primali 100 mg/m2 i 121 bolesnika koji su primali 75 mg/m2 docetaksela kao monoterapiju,
1,4 sorbitan
želatina glicerol sorbitol
1,407 patients undergoing abdominal surgery treated up to 9 days
u 1407 bolesnika nakon abdominalnog kirurškog zahvata liječenih do 9 dana
1,500 mg twice daily
1500 mg dva puta na dan
1,500 mg/m2 and doxorubicin 25 mg/m2, palonosetron 250 micrograms and 750 micrograms were compared with ondansetron 32 mg (half-life 4 hours) or dolasetron 100 mg (half-life 7.3 hours) administered intravenously on Day 1, without dexamethasone.
ondansetronom 32 mg (poluvijek 4 sata) ili dolasetronom 100 mg (poluvijek 7,3 sata) primijenjeno intravenski na dan 1, bez deksametazona.
1,500 twice daily
1500 mg dva puta na dan
1,600 mg/m2
1600 mg/m2
1,600 units*,
1600 jedinica*,
1,600 – 2,400 IU
1600-2400 IU
1,895 vaccinated with 3 doses
1895 cijepljenih s 3 doze
1- Preferred terms considered as injection site reactions are presented in section below
1Preporučeni izrazi koji se smatraju reakcijama na mjestu primjene injekcije prikazani su u dijelu ispod.
1-10 million cells/ml
1-10 milijuna stanica/ml
1-15, Avenue Edouard Belin 92500 Rueil-Malmaison France
1-15, Avenue Edouard Belin 92500 Rueil-Malmaison Francuska
1-2 mg clomipramine/kg bw twice daily.
1 - 2 mg klomipramina/kg tjelesne mase dva puta dnevno.
1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
26,9; 26,7), 6% (CI: –33,5; 34,3) i 14% (CI: –31,6; 44,2) tijekom razdoblja u studiji od 0 do 1 mjesec, do 3 mjeseca, 3 do 6 mjeseci, 6 do 9 mjeseci, odnosno 9 do 12 mjeseci.
1-5% of patients treated with Pegasys developed neutralising anti-interferon antibodies.
1-5% bolesnika liječenih lijekom Pegasys razvilo je neutralizirajuća antitijela.
1-5, with increasing duration and earlier start of imatinib from cohort to cohort; cohort 1 receiving the lowest intensitiy and cohort 5 receiving the highest intensity of imatinib (longest duration in days with continuous daily imatinib dosing during the first chemotherapy treatment courses).
Imatinib je povremeno primjenjivan u kohortama 1-5, uz progresivno produljenje i raniji početak primjene imatiniba od jedne do druge kohorte, pri čemu je kohorta 1 primala najmanji intenzitet, a kohorta 5 najveći intenzitet imatiniba (najdulje trajanje u danima kontinuiranog uzimanja dnevne doze imatiniba tijekom prvih ciklusa kemoterapije).
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
1-palmitoil-2-oleoil-sn-glicero-3-fosfokolin (POPC)
1-sided p-valueb
Jednostrana p-vrijednostb
1-sided p-valuec
Jednostrana p-vrijednostc
1-year
1 godina
1-year OS rate, % (95% CI)
1-godina stopa ukupnog 77,6 (71,4; 82,7)
1-year OS rate, % (95% CI)
Omjer hazarda (95% CI)
1-year Overall Survival (%)e 76.7 72.6
1-godišnje opće preživljenje (%)e 76,7 72,6
1-year Overall survival rate (%)
1-godišnja stopa ukupnog preživljenja
1-year PFS Rate
1-godišnja stopa PFS-a
1-year survival
(95% CI)
1-year Survival (%)
jednogodišnje preživljenje
1.) Add approximately 0.8 ml sodium chloride 9 mg/ml (0.9%) solution to developing chamber assuring the liquid will not touch the 1.4 cm origin mark on the ITCL strip.
1.) Dodajte približno 0,8 ml otopine natrijevog klorida od 9 mg/ml (0,9 %) u komoru za razvijanje pazeći da tekućina ne dodiruje oznaku početka od 1,4 cm na trakici za ITCL.
1.0 g
1,0 g
1.0 mg QD
1,0 mg 1x/dan
1.0 mL
1,0 mL
1.0 ml
10000 IU/1 ml
1.0 mL (10 million IU/mL)
0,5 ml (10 milijuna IU/ml)
1.0 ml (10000 IU)
1.0 ml (10000 IU/ml)
1.0 ml (10000 IU/ml) 6 pre-filled syringes
1,0 ml (40 000 IU/ml)
1.0 ml (40000 IU/ml) 1 pre-filled syringe
1,0 ml (40 000 IU/ml)
1.0 ml (40000 IU/ml) 1 pre-filled syringe
6 napunjenih štrcaljki
1.0 ml (40000 IU/ml) 4 pre-filled syringes
1,0 ml (10 000 IU/ml)
1.0 ml (40000 IU/ml) 4 pre-filled syringes
napunjene štrcaljke
1.0 ml (40000 IU/ml) 6 pre-filled syringes
1,0 ml (10 000 IU/ml)
1.0 ml (40000 IU/ml) 6 pre-filled syringes
napunjenih štrcaljki
1.0 mL of solution in a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a black polypropylene plunger rod.
1 ml otopine u graduiranoj štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i crnim klipom od polipropilena
1.0 ml/kg body weight
1,0 ml/kg tjelesne težine
1.0 ng/ml were transient.
1,0 ng/ml, pokazalo se da su prolazne.
1.0 Placebo (n=111)
1,0 Placebo (n=111)
1.0 point improvement
poboljšanje od 1,0 bod
1.0 µg/kg
1,0 µg/kg
1.00
ombitasvir
1.00 % (mean at baseline = 8.5%)
1,00% (srednja početna vrijednost = 8,5%)
1.01
NP
1.01 (0.91-1.11)
ritonavirom.
1.02)]; CrCL ≥ 80 mL/min [HR (95% CI): 1.15 (0.95, 1.40)].
< 80 ml/min [HR (95% CI): 0,87 (0,75, 1,02)]; CrCL ≥ 80 ml/min [HR (95% CI): 1,15 (0,95, 1,40)].
1.03
ombitasvir
1.03
ritonavirom
1.047 (0.898, 1.220)
Svekupno
1.05
jedanput na
1.05
tonavir.
1.07
NP
1.07 (0.77,1.48), p = 0.6880
1,07 (0,77, 1,48), p = 0,6880
1.07, (95% CI: 0.75,
1,07, (95% CI: 0,75;
1.08 mL of solution in 1.5 mL cartridge (type I glass) with a grey rubber piston and an aluminium crimp-cap with a rubber inlay.
1,08 ml otopine u ulošku volumena 1,5 ml (staklo tipa I ) sa sivim gumenim klipom i aluminijskim zatvaračem s gumenim umetkom.
1.09
Ctrough
1.0–1.5 mg/kg bodyweight/day
vinjske dizenterije
1.1 (P=0.3423)
1,1 (P = 0,3423)
1.1 b
1,1 b
1.1% vs 23.5%
1,1% vs 23,5
1.12 (1 pipette)
1,12 mL (1 pipeta)
1.13 (0.74, 1.73) p = 0.562
1,13 (0,74,1,73) p = 0,562
1.13 (1.01-1.25)
PRIMIJE- NJEN UZ
1.13) for AUC24,ss, 0.878 (0.827; 0.930) for Ctrough,ss, and 1.18 (1.12;1.24) for Cmax,ss.
Cnajniža,ss, i 1,18 (1,12;1,24) za Cmax,ss.
1.14
progestin)
1.15
ritonavirom.
1.15 (0.85, 1.56)
(17,5 naspram.15,0 mjeseci;
1.16 milligrams sodium per millilitre.
1,16 miligrama natrija po mililitru otopine.
1.17
CYP3A4
1.17
ombitasvir
1.17 (1.09-1.26)
ombitasvir/par itaprevir/riton avir
1.18
tonavir
1.1, p0.001).
1,1%, p<0,001).
1.2
Opći
1.2 litres/hour.
1,20 litara/sat.
1.2 mL (15 million
1,2 ml (15 milijuna IU/ml)
1.2 mL (15 million IU/mL)
1,2 ml (15 milijuna IU/ml)
1.2 mL (25 million IU/mL)
1,2 ml (25 milijuna IU/ml)
1.2 mL (50 million IU/mL)
1,2 ml (50 milijuna IU/ml)
1.2 mL in a 2 mL graduated syringe for Somatropin Biopartners 20 mg
1,2 ml u graduiranoj štrcaljki od 2 ml za Somatropin Biopartners 20 mg
1.2 mL of solution (corresponding to 18 MIU) is contained in a pen made of a cartridge (type I glass) sealed at one end with a cap (aluminium) containing a liner (bromobutyl rubber) and at the other end by a plunger (bromobutyl rubber).
1,2 ml otopine (što odgovara 18 milijuna IU) sadržane u brizgalici koja se sastoji od uloška (staklo tipa I), koji je s jedne strane zatvoren (aluminijskom) kapicom obloženom gumom (brombutilna guma), a s druge klipom (brombutil guma).
1.2 mL of solution (corresponding to 30 MIU) is contained in a pen made of a cartridge (type I glass) sealed at one end with a cap (aluminium) containing a liner (bromobutyl rubber) and at the other end by a plunger (bromobutyl rubber).
1,2 ml otopine (što odgovara 30 milijuna IU) sardžane u brizgalici koja se sastoji od uloška (staklo tipa I), koji je s jedne strane zatvoren (aluminijskom) kapicom obloženom gumom (brombutilna guma), a s druge klipom (brombutil guma).
1.2 mL of solution (corresponding to 60 MIU) is contained in a pen made of a cartridge (type I glass) sealed at one end with a cap (aluminium) containing a liner (bromobutyl rubber) and at the other end by a plunger (bromobutyl rubber).
1,2 ml otopine (što odgovara 60 milijuna IU) sadržane u brizgalici koja se sastoji od uloška (staklo tipa I), koji je s jedne strane zatvoren (aluminijskom) kapicom obloženom gumom (brombutilna guma), a s druge klipom (brombutil guma).
1.2 mm x 40 mm, 5 µm, provided) onto the 1 ml syringe (provided) using aseptic technique.
Na štrcaljku od 1 ml (priložena) stavite iglu s filterom promjera pora 5 µm (18G x 1½″, 1,2 mm x 40 mm, 5 µm, priložena) koristeći aseptičku tehniku.
1.2 to 5 kg
1,2 do 5 kg
1.21
1  a.
1.21
Mehanizam:
1.22
biti
1.22
trimetoprim
1.23 (1.00–1.51)
stanica
1.23 mg/m2, but this may be adjusted by your doctor based on your blood test results or other factors.
1,23 mg/m2, ali liječnik je može prilagoditi ovisno o Vašim krvnim nalazima ili drugim čimbenicima.
1.23 x [140 - age (years)] x weight (kg)
1,23 x [140 - dob (godine)] x težina (kg)
1.23  (140-age [years])  weight [kg] ( 0.85 if female) serum creatinine [mol/L]
1,23  (140-dob [godine])  težina [kg] ( 0,85 za žene) kreatinin u serumu [mol/L]
1.230 mL (833 IU/mL)
1,230 ml (833 IU/ml)
1.24
paritaprevir
1.25 mg).
Nakon
1.25 mL
1,25 mL
1.25 ml
Potkožno